Phase II study of single-agent bosutinib, a src/abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 610-617

  Campone, M ^a,b   Bondarenko, I ^c   Brincat, S ^d   Hotko, Y ^e   Munster, P N ^f   Chmielowska, E ^g   Fumoleau, P ^h   Ward, R ⁱ   Bardy bouxin, N ^j   Leip, E ^j   Turnbull, K ^j   Zacharchuk, C ^j   Epstein, R J ^k  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b Team 12   (France)

^c Dnipropetrovsk State Medical Academy   (Ukraine)

^d Sir Paul Boffa Hospital   (Malta)

^e UZHGOROD NATIONAL UNIVERSITY   (Ukraine)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g Multi Med Salata i Wsp sp Jawna   (Poland)

^h CENTRE GEORGES FRANÇOIS LECLERC   (France)

ⁱ ST VINCENT S HOSPITAL   (Australia)

^j PFIZER INC   (United States)

^k UNIVERSITY OF HONG KONG   (Hong Kong)

more..

Author keywords

Abl; Bosutinib; Breast neoplasms; Src; Tyrosine kinase inhibitors

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BOSUTINIB; HORMONE RECEPTOR;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HUMAN; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; NAUSEA; NEUTROPENIA; OSSIFICATION; OSTEOLYSIS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84857546448     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr261     Document Type: Article

References (24)

1. Reichardt P, Von Minckwitz G, Thuss-Patience PC et al. Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14: 1227-1233.
2. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 2006; 56: 37-47.
3. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
4. Dawood S, Kristine B, Hortobagyi G et al. Prognosis of women with stage IV breast cancer by HER2 status and trastuzumab treatment: an institutional based review. J Clin Oncol 2008; 26: (Abstr 1018).
5. Boschelli DH, Ye F, Wang YD et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 2001; 44: 3965-3977.
6. Golas JM, Arndt K, Etienne C et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003; 63: 375-381.
7. Jallal H, Valentino ML, Chen G et al. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007; 67: 1580-1588.
8. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002; 1602: 114-130.
9. Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010; 36: 177-184.
10. Shakespeare WC, Metcalf CA III, Wang Y et al. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery. Curr Opin Drug Discov Devel 2003; 6: 729-741.
11. Ottenhoff-Kalff AE, Rijksen G, van Beurden EA et al. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 1992; 52: 4773-4778.
12. Messersmith W, Krishnamurthi S, Hewes B et al. Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: preliminary results from a phase 1 study in patients with advanced malignant solid tumors. J Clin Oncol 2007; 25: (Abstr 3552).
13. Miyazaki T, Sanjay A, Neff L et al. Src kinase activity is essential for osteoclast function. J Biol Chem 2004; 279: 17660-17666.
14. Myoui A, Nishimura R, Williams PJ et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003; 63: 5028-5033.
15. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64: 693-702.
16. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
18. Finn RS, Bengala C, Ibrahim N et al. Phase II trial of dasatinib in triplenegative breast cancer: results of study CA180059. Cancer Res 2009; 69: (Abstr 3118).
19. Mayer E, Baurain J, Sparano J et al. Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: phase II study CA180088. J Clin Oncol 2009; 27: 43s (Abstr 1011).
20. Lombardo LJ, Lee FY, Chen P et al. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-6661.
21. Maekawa T, Ashihara E, Kimura S. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol 2007; 12: 327-340.
22. Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
23. Jayson GC, Parker GJ, Mullamitha S et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005; 23: 973-981.
24. Somlo G, Atzori F, Strauss L et al. Dasatinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): phase I study CA180004. J Clin Oncol 2009; 27: (Abstr 1012).